HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Biochemical outcome after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy: 12 years of experience.

AbstractUNLABELLED:
Study Type - Therapy (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Biochemical control from series in which radical prostatectomy is performed for patients with unfavorable prostate cancer and/or low dose external beam radiation therapy are given remains suboptimal. The treatment regimen of HDR brachytherapy and external beam radiotherapy is a safe and very effective treatment for patients with high risk localized prostate cancer with excellent biochemical control and low toxicity.
OBJECTIVE:
• To investigate the long-term oncological outcome, during the PSA era, of patients with prostate cancer who were treated using high-dose-rate (HDR) brachy therapy (BT) combined with external beam radiation therapy (EBRT).
PATIENTS AND METHODS:
• From June 1998 to April 2007, 313 patients with localized prostate cancer were treated with 46 Gy of EBRT to the pelvis with a HDR-BT boost. • The mean (median) follow-up was 71 (68) months. • Toxicity was reported according to the Common Toxicity Criteria for Adverse Event, V.4.
RESULTS:
• The 10-year actuarial biochemical control was 100% for patients with no high-risk criteria, 88% for patients with two intermediate-risk criteria, 91% with one high-risk criterion and 79% for patients with two to three high-risk criteria (P= 0.004). • The 10-year cancer-specific survival was 97% (standard deviation ± 1%). • The multivariate Cox regression analyses identified, Gleason score and T stage as independent prognostic factors for biochemical failure. • Gleason score was the only factor to significantly affect distant metastases. • Grade ≥ 3 late toxicity was not detected.
CONCLUSION:
• The 10-year results confirm the feasibility and effectiveness of EBRT with conformal HDR-BT boost for patients with localised prostate cancer.
AuthorsPedro J Prada, Herminio González, José Fernández, Isabel Jiménez, Aránzazu Iglesias, Inmaculada Romo
JournalBJU international (BJU Int) Vol. 109 Issue 12 Pg. 1787-93 (Jun 2012) ISSN: 1464-410X [Electronic] England
PMID21981583 (Publication Type: Journal Article)
Copyright© 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.
Chemical References
  • Prostate-Specific Antigen
Topics
  • Age of Onset
  • Aged
  • Brachytherapy (adverse effects, methods)
  • Disease-Free Survival
  • Dose-Response Relationship, Radiation
  • Gastrointestinal Diseases (etiology)
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Recurrence, Local (mortality)
  • Prostate-Specific Antigen (metabolism)
  • Prostatic Neoplasms (mortality, pathology, radiotherapy)
  • Radiotherapy Dosage
  • Sexual Dysfunction, Physiological (etiology)
  • Treatment Outcome
  • Urologic Diseases (etiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: